AVEO Oncology
AVEO
$15.00
Share price
0.00%
Change (1 day)
170.76%
Change (1 year)
Categories
AVEO Oncology (AVEO) - P/B ratio
P/B ratio as of April 2024 : 18.1
According to AVEO Oncology
's latest financial reports the company has a price-to-book ratio of 18.1.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
AVEO Oncology - P/B ratio (from 2010 to 2022)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2022-12-31 | 18.0 | 412.64% |
| 2021-12-31 | 3.51 | -25.38% |
| 2020-12-31 | 4.71 | -30.36% |
| 2019-12-31 | 6.76 | -190.98% |
| 2018-12-31 | -7.43 | -8.22% |
| 2017-12-31 | -8.10 | -61.98% |
| 2016-12-31 | -21.3 | -600.6% |
| 2015-12-31 | 4.26 | 99.6% |
| 2014-12-31 | 2.13 | 57.27% |
| 2013-12-31 | 1.36 | -54.25% |
| 2012-12-31 | 2.96 | -10.86% |
| 2011-12-31 | 3.32 | -54.17% |
| 2010-12-31 | 7.25 | |
| 2009-12-31 | N/A | |
| 2008-12-31 | N/A |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Eli Lilly LLY | 64.1 | 254.65% | 🇺🇸 USA |
 Amgen AMGN | 23.2 | 28.54% | 🇺🇸 USA |
 Biogen BIIB | 2.06 | -88.63% | 🇺🇸 USA |
 Regeneron Pharmaceuticals REGN | 3.73 | -79.34% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 3.09 | -82.93% | 🇺🇸 USA |
 Merrimack Pharmaceuticals MACK | 11.4 | -36.82% | 🇺🇸 USA |